Table 1.
Characteristics of first-line systemic therapy for metastatic renal cell carcinoma studies included in the network meta-analysis.
| Study | Year | Condition | Treatment | Sample size | Follow-up (month) |
Dosage | Outcomes | Treatment level |
|---|---|---|---|---|---|---|---|---|
| Rini (14) | 2016 | metastatic renal cell carcinoma | Sunitinib | 204 | 33.3 | 50 mg Qd | PFS, OS, grade ≥ 3 AEs | first-line therapy |
| IMA901+Sunitinib | 135 | Sunitinib 50 mg Qd and IMA901 4.13 mg intr | ||||||
| Yang (15) | 2003 | metastatic renal cell carcinoma | Bevacizumab | 39 | 27 | 3 mg/kg Q2W | PFS, OS, ORR | first-line therapy |
| Placebo | 40 | matching Placebo | ||||||
| Choueiri (16) | 2018 | metastatic renal cell carcinoma | Cabozantinib | 79 | 21.4 | 60 mg Qd | PFS, OS, ORR, grade ≥ 3 AEs | first-line therapy |
| Sunitinib | 79 | 50 mg Qd | ||||||
| Tamada (17) | 2022 | metastatic renal cell carcinoma | Pembrolizumab+Axitinib | 44 | 29.5 | Pembrolizumab 200 mg Q3W + Axitinib 5 mg Bid | PFS, ORR, grade ≥ 3 AEs | first-line therapy |
| Sunitinib | 50 | 50 mg Qd | ||||||
| Sternberg (18) | 2010 | metastatic renal cell carcinoma | Pazopanib | 290 | 6.4 | 800 mg Qd | PFS, ORR, grade ≥ 3 AEs | first-line therapy |
| Placebo | 145 | matching Placebo | ||||||
| Sheng (19) | 2020 | metastatic renal cell carcinoma | Sunitinib | 100 | 29.5 | 50 mg Qd | PFS, OS, ORR, grade ≥ 3 AEs | first-line therapy |
| Pazopanib | 109 | 800 mg Qd | ||||||
| Motzer (20) | 2013 | metastatic renal cell carcinoma | Pazopanib | 557 | 29.5 | 801 mg Qd | PFS, ORR, grade ≥ 3 AEs | first-line therapy |
| Sunitinib | 553 | 50 mg Qd | ||||||
| Motzer (21) | 2014 | metastatic renal cell carcinoma | Pazopanib | 557 | 29.5 | 800 mg QD | OS | first-line therapy |
| Sunitinib | 553 | 50 mg Qd | ||||||
| Cirkel (22) | 2016 | metastatic renal cell carcinoma | Pazopanib+Everolimus | 52 | 20.2 | Pazopanib 800mg Qd + Everolimus 10 mg Qd | PFS, grade ≥ 3 AEs | first-line therapy |
| Pazopanib | 49 | 800mg Qd | ||||||
| Powles (11) | 2020 | advanced renal cell carcinoma | Pembrolizumab+Axitinib | 432 | 30.6 | 200 mg intr Q3W | PFS, OS, ORR, grade ≥ 3 AEs | first-line therapy |
| Sunitinib | 429 | 5 mg Axitinib Qd or 50 mg Sunitinib Qd | ||||||
| Choueiri (23) | 2020 | metastatic renal cell carcinoma | Savolitinib | 33 | 20.6 | 600mg Qd | PFS, OS, ORR, grade ≥ 3 AEs | first-line therapy |
| Sunitinib | 27 | 50 mg Qd | ||||||
| Escudier (24) | 2007 | advanced renal cell carcinoma | Sorafenib | 451 | 6.6 | 400 mg Bid | PFS, OS, ORR, grade ≥ 3 AEs | first-line therapy |
| Placebo | 452 | matching Placebo | ||||||
| Cai (25) | 2018 | metastatic renal cell carcinoma | Sorafenib | 110 | 23 | 400 mg Bid | OS | first-line therapy |
| Sunitinib | 74 | 50 mg Qd | ||||||
| Rini (26) | 2019 | metastatic renal cell carcinoma | Atezolizumab+Bevacizumab | 454 | 24 | Atezolizumab 1200 mg + Bevacizumab 15 mg/kg intr Q3W | PFS, OS, ORR, grade ≥ 3 AEs | first-line therapy |
| Sunitinib | 461 | 50 mg Qd | ||||||
| McDermott (27) | 2018 | metastatic renal cell carcinoma | Atezolizumab+Bevacizumab | 101 | 20.7 | Atezolizumab 1,200 mg intr + Bevacizumab 15 mg/kg Q3W | PFS, ORR, grade ≥ 3 AEs | first-line therapy |
| Sunitinib | 101 | 50 mg Qd | ||||||
| Atezolizumab | 103 | 1,200 mg intr Q3W | ||||||
| Choueiri (12) | 2020 | advanced renal cell carcinoma | Avelumab+Axitinib | 442 | 18.5 | Avelumab 10 mg/kg intr Q2W + Axitinib 5 mg Bid | PFS, OS, ORR | first-line therapy |
| Sunitinib | 444 | 50 mg Qd | ||||||
| Numakura (28) | 2021 | metastatic renal cell carcinoma | Axitinib | 134 | 20 | 5 mg Bid | PFS, OS, ORR | first-line therapy |
| Sunitinib | 274 | 50 mg Qd | ||||||
| Hutson (29) | 2013 | metastatic renal cell carcinoma | Axitinib | 192 | 37 | 5 mg Bid | PFS, ORR | first-line therapy |
| Sorafenib | 96 | 400 mg Bid | ||||||
| Hutson (30) | 2016 | metastatic renal cell carcinoma | Axitinib | 192 | 37 | 5 mg Bid | OS, grade ≥ 3 AEs | first-line therapy |
| Sorafenib | 96 | 400 mg Bid | ||||||
| Rini (31) | 2011 | advanced renal cell carcinoma | Axitinib | 361 | 30 | 5 mg Bid | PFS, ORR | first-line therapy |
| Sorafenib | 362 | 400 mg Bid | ||||||
| Rini (32) | 2013 | advanced renal cell carcinoma | Axitinib | 361 | 30 | 5 mg Bid | OS, grade ≥ 3 AEs | first-line therapy |
| Sorafenib | 362 | 400 mg Bid | ||||||
| Zhou (33) | 2019 | metastatic renal cell carcinoma | Anlotinib | 90 | 30.5 | 12 mg Qd | PFS, OS, ORR, grade ≥ 3 AEs | first-line therapy |
| Sunitinib | 43 | 50 mg Qd | ||||||
| Motzer (8) | 2021 | advanced renal cell carcinoma | Lenvatinib+Pembrolizumab | 355 | 26.6 | Lenvatinib 20 mg Qd + Pembrolizumab 200 mg intr Q3W | PFS, OS, ORR, grade ≥ 3 AEs | first-line therapy |
| Sunitinib | 357 | 50 mg Qd | ||||||
| Lenvatinib+Everolimus | 357 | Lenvatinib 18 mg Qd + Everolimus 5 mg Qd | ||||||
| Motzer (9) | 2022 | advanced renal cell carcinoma | Nivolumab+Cabozantinib | 323 | 32.9 | Nivolumab 240 mg intr Q2W + Cabozantinib 40 mg Qd | PFS, OS, ORR, grade ≥ 3 AEs | first-line therapy |
| Sunitinib | 328 | 50 mg Qd | ||||||
| Albiges (10) | 2020 | advanced renal cell carcinoma | Nivolumab+lpilimumab | 550 | 55 | Nivolumab 3 mg/kg Q3W + Ipilimumab 1 mg/kg Q3W | PFS, OS, ORR, grade ≥ 3 AEs | first-line therapy |
| Sunitinib | 546 | 50 mg Qd | ||||||
| Vano (34) | 2022 | metastatic renal cell carcinoma | Nivolumab+lpilimumab | 41 | 18 | Nivolumab 3 mg/kg Q3W + Ipilimumab 1 mg/kg Q3W | PFS, ORR, grade ≥ 3 AEs | first-line therapy |
| Nivolumab | 42 | Nivolumab 240 mg Q2W |
Qd, quaque die; Bid, bis in die; Q3W, every three weeks; Q2W, every two weeks; PFS, progression free survival; OS, overall survival; ORR, objective response rate; AE, adverse event.